We have shown that this phenomenon impacts the treatment of patients, who may be reclassified from profound to partial BTD deficiency with resulting change in the recommended dose of biotin or even achieve a residual BTD enzyme activity above 30% of control, resulting in a halt of biotin supplementation. This evidence concerns the gene BTD and biotinidase deficiency.